UTHR

United Therapeutics Corporation

UTHR.US unither.com + Research + Basket
CIK 0001082554
Employees 1,400
Phone 301 608 9292
Fiscal year end December
IPO Jun 17, 1999
Address 1000 Spring Street, Silver Spring, MD, United States, 20910
600.86
+7.32 (+1.23%)
USD · NASDAQ
52-week range
430.02
609.35
Trading at 95% of the 52-week range
Market Cap
25.46B
P/E Ratio
21.26
Forward P/E
18.59
Book Value
149.97
Div. Yield
N/A
% Institutions
100.29%
% Insiders
2.00%

1 Year

+30.4%

3 Year

+169.0%

10 Year

+394.3%
Description

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Actions

Add an action for UTHR.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. Founder, Chairman & CEO 1955
Mr. Michael I. Benkowitz President & COO 1972
Mr. James C. Edgemond CFO & Treasurer 1968
Mr. Paul A. Mahon J.D. Executive VP, General Counsel & Corporate Secretary 1964
Harrison Silvers Manager of Investor Relations NA
Ms. Holly Hobson Associate Vice President of Human Resources NA
Mr. Patrick Poisson Executive Vice President of Strategic Development 1968
Dr. Leigh Peterson Executive Vice President of Product Development & Xenotransplantation NA
Mr. Gil Golden Senior VP & Chief Medical Officer NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Apr 24, 2026 Christopher Patusky N/A Sale 2.91K $569.00 $1.66M SEC
Apr 23, 2026 James Edgemond N/A Sale 9.64K $572.21 $5.51M SEC
Apr 22, 2026 James Edgemond N/A Sale 364.00 $575.85 $209.61K SEC
Apr 22, 2026 Martine A Rothblatt N/A Sale 9.50K $576.56 $5.48M SEC
Apr 20, 2026 James Edgemond N/A Sale 10.00K $577.86 $5.78M SEC
Apr 20, 2026 Martine A Rothblatt N/A Sale 9.50K $577.83 $5.49M SEC
Apr 17, 2026 Christopher Patusky N/A Sale 1.00K $578.88 $578.88K SEC
Apr 17, 2026 Martine A Rothblatt N/A Sale 9.50K $586.66 $5.57M SEC
Apr 16, 2026 James Edgemond N/A Sale 10.00K $577.18 $5.77M SEC
Apr 16, 2026 Paul A Mahon N/A Sale 8.30K $576.82 $4.79M SEC
Apr 15, 2026 Martine A Rothblatt N/A Sale 9.50K $580.36 $5.51M SEC
Apr 13, 2026 James Edgemond N/A Sale 10.00K $574.88 $5.75M SEC
Apr 13, 2026 Martine A Rothblatt N/A Sale 9.50K $574.86 $5.46M SEC
Apr 10, 2026 Martine A Rothblatt N/A Sale 9.50K $569.28 $5.41M SEC
Apr 09, 2026 James Edgemond N/A Sale 10.00K $577.89 $5.78M SEC
Apr 08, 2026 Martine A Rothblatt N/A Sale 9.50K $580.45 $5.51M SEC
Apr 06, 2026 James Edgemond N/A Sale 10.00K $558.40 $5.58M SEC
Apr 06, 2026 Martine A Rothblatt N/A Sale 9.50K $558.41 $5.30M SEC
Apr 02, 2026 James Edgemond N/A Sale 10.00K $561.50 $5.62M SEC
Apr 02, 2026 Paul A Mahon N/A Sale 8.30K $565.87 $4.70M SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 5.29M Jun 30, 2026 12.34% $0.04 -1.95%
venBio Select Advisor LLC 2.78M Jun 30, 2026 6.48% $13.52 5.62%
Vanguard Portfolio Management, LLC 1.92M Jun 30, 2026 4.48% $0.05 -4.21%
Vanguard Capital Management, LLC 1.92M Jun 30, 2026 4.47% $0.02 -2.01%
State Street Corp 1.90M Jun 30, 2026 4.43% $0.03 2.93%
Renaissance Technologies Corp 1.71M Jun 30, 2026 3.98% $1.28 -4.38%
Wellington Management Company LLP 1.38M Jun 30, 2026 3.22% $0.13 -39.10%
Geode Capital Management, LLC 996.60K Jun 30, 2026 2.32% $0.03 -19.17%
HHG PLC 866.93K Mar 31, 2026 2.02% $0.25 8.90%
Jupiter Topco LLC 831.13K Jun 30, 2026 1.94% $0.18 0.00%
NORGES BANK 694.75K Jun 30, 2026 1.62% $0.04 15.37%
Genworth Financial Wealth Mgmt Inc 624.07K Jun 30, 2026 1.46% $0.58 1.30%
AQR Capital Management LLC 546.00K Jun 30, 2026 1.27% $0.10 -33.92%
Dimensional Fund Advisors, Inc. 527.90K Jun 30, 2026 1.23% $0.05 2.96%
FMR Inc 473.41K Jun 30, 2026 1.10% $0.01 -10.40%
Amvescap Plc. 473.11K Jun 30, 2026 1.10% $0.02 -22.23%
Baillie Gifford & Co Limited. 467.21K Jun 30, 2026 1.09% $0.23 9.13%
Deerfield Management Co 457.00K Jun 30, 2026 1.07% $2.58 0.00%
Morgan Stanley - Brokerage Accounts 436.70K Jun 30, 2026 1.02% $0.01 6.70%
Vestal Point Capital LP 435.00K Jun 30, 2026 1.01% $5.51 480.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Core S&P Mid-Cap ETF 1.53M 3.56% ▼ 0.04% Sep 30, 2026
2 Vanguard MStar Total Stk Mkt Idx Invest 1.36M 3.18% ▲ 1.01% Sep 30, 2026
3 Vanguard Small Cap Index 965.42K 2.25% ▼ 1.15% Sep 30, 2026
4 Vanguard Health Care Inv 756.63K 1.76% ▼ 11.58% Jun 30, 2026
5 iShares Biotechnology ETF 323.43K 0.75% ▼ 0.75% Sep 30, 2026
6 State Street® SPDR® S&P MIDCAP 400® ETF 317.13K 0.74% ▲ 2.16% Sep 30, 2026
7 Vanguard MStar Small Cap Value Index 314.15K 0.73% ▲ 1.30% Sep 30, 2026
8 Vanguard US Growth Investor 304.13K 0.71% ▲ 0.00% Jun 30, 2026
9 Invesco S&P MidCap Quality ETF 296.33K 0.69% ▲ 0.10% Sep 30, 2026
10 State Street® SPDR® S&P® Biotech ETF 293.48K 0.68% ▼ 1.87% Sep 30, 2026

Financial Highlights

▼
Market Cap: $25.46B
EBITDA: $1.50B
P/E Ratio: $21.26
PEG Ratio: $2.22
Book Value: $149.97
Earnings/Share: $27.92
Profit Margin: 41.56%
Operating Margin: 42.23%
ROA (TTM): 11.61%
ROE (TTM): 19.32%
Revenue (TTM): $3.15B
Revenue/Share (TTM): $72.85
Earnings Growth (YOY): 13.40%
Revenue Growth (YOY): -1.90%

Valuation Metrics

Enterprise Value: $22.03B
Trailing P/E: 21.26
Forward P/E: 18.59

Shares Statistics

Shares Outstanding: 42.89M
Shares Float: 39.21M
% Insiders: 2.00%
% Institutions: 100.29%
Shares Short: 2.46M
Shares Short (Prior Month): 3.60M
Short Ratio: 2.42
Short % Float: 6.69%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$3.18B
Cost of Goods Sold
adjust
$-384.40M
Gross Profit
subtotal
$2.80B
SG&A
adjust
$-612.50M
R&D
adjust
$-550.00M
Other Operating Expense
adjust
$-118.60M
Operating Income
subtotal
$1.52B
Other / Non-Operating Items
adjust
$-182.50M
Net Income
subtotal
$1.33B

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about UTHR.US!